公开(公告)号：US11040969B2

公开(公告)日：2021-06-22

申请号：US16514413

申请日：2019-07-17

申请人： BENEVOLENTAI CAMBRIDGE LIMITED

发明人： Edward Savory ,  Michael Higginbottom ,  Kathryn Oliver ,  Viet-Anh Anne Horgan

IPC分类号： C07D471/04 ,  A61K31/437

摘要： The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.

公开(公告)号：US10399973B2

公开(公告)日：2019-09-03

申请号：US15858407

申请日：2017-12-29

申请人： BENEVOLENTAI CAMBRIDGE LIMITED

发明人： Edward Savory ,  Michael Higginbottom ,  Kathryn Oliver ,  Viet-Anh Anne Horgan

IPC分类号： A61K31/437 ,  C07D471/04

摘要： The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.